Tebipenem Pivoxil Hydrobromide: Review of a New Oral Carbapenem in Development
by Jose Roig, 2022 PharmD Candidate, Justin Sorenson, 2022 PharmD Candidate, Melissa Staffin, 2022 PharmD Candidate, Alyssa Amrhein, 2022 PharmD Candidate, Kristen Bunnell, PharmD, BCCCP, BCIDP
"Since the 1985 approval of the first carbapenem antibiotic, imipenem, carbapenems have played an important role in the treatment of serious bacterial infections. Compared to other β-lactam antibiotics, carbapenems have the most broad-spectrum in vitro activity against gram-negative bacteria, including those that express extended-spectrum β-lactamases (ESBLs).1 Guidelines from the Infectious Diseases Society of America for gram- negative bacterial infections published in 2020 considered carbapenems the preferred antibiotic class to treat infections caused by ESBL-producing bacteria outside of the urinary tract.2 All of the currently approved carbapenems in the United States (U.S.) are available only in an intravenous dosage form. This can pose a challenge for patients who require treatment with a carbapenem in the outpatient setting, due to the need for a central intravenous line, coordination of outpatient infusion services, and limited stability of many carbapenems after reconstitution.3 An oral carbapenem would thus provide a welcome alternative for the treatment of outpatients with challenging infections."
Keywords: tebipenem, Anti-Bacterial Agents, Penicillin-Binding Proteins, Meropenem, Outpatients, Imipenem, Ciprofloxacin, Fluoroquinolones, Porins, United States Food and Drug Administration, Gram-Negative Bacteria, Gram-Positive Bacteria, Carbapenems, Lactams, Urinary Tract Infections, Gram-Negative Bacterial Infections, Bacterial Infections, Communicable Diseases, Pneumonia, Product Surveillance, Postmarketing, Respiratory System
Download PDF
2021 May/June Table of Contents
"Since the 1985 approval of the first carbapenem antibiotic, imipenem, carbapenems have played an important role in the treatment of serious bacterial infections. Compared to other β-lactam antibiotics, carbapenems have the most broad-spectrum in vitro activity against gram-negative bacteria, including those that express extended-spectrum β-lactamases (ESBLs).1 Guidelines from the Infectious Diseases Society of America for gram- negative bacterial infections published in 2020 considered carbapenems the preferred antibiotic class to treat infections caused by ESBL-producing bacteria outside of the urinary tract.2 All of the currently approved carbapenems in the United States (U.S.) are available only in an intravenous dosage form. This can pose a challenge for patients who require treatment with a carbapenem in the outpatient setting, due to the need for a central intravenous line, coordination of outpatient infusion services, and limited stability of many carbapenems after reconstitution.3 An oral carbapenem would thus provide a welcome alternative for the treatment of outpatients with challenging infections."
Keywords: tebipenem, Anti-Bacterial Agents, Penicillin-Binding Proteins, Meropenem, Outpatients, Imipenem, Ciprofloxacin, Fluoroquinolones, Porins, United States Food and Drug Administration, Gram-Negative Bacteria, Gram-Positive Bacteria, Carbapenems, Lactams, Urinary Tract Infections, Gram-Negative Bacterial Infections, Bacterial Infections, Communicable Diseases, Pneumonia, Product Surveillance, Postmarketing, Respiratory System
Download PDF
2021 May/June Table of Contents